Physician profile
Amanda M Trolinger
NPI 1417267386
$3,028.64
in general payments reported to CMS, 2019-2025
20 companies · $561 in 2025
The $561 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $303 · 2022: $205 · 2023: $1,386 · 2024: $574 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,320 · Consulting Fee: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,320.41 |
| Consulting Fee | $1,200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $1,200.00 | 2023 | |
| Amgen INC. | $357.92 | 2021-2025 | Krystexxa, Aranesp, Tavneos |
| Astrazeneca Pharmaceuticals Lp | $220.22 | 2021-2023 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $195.46 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.64 | 2024-2025 | Jardiance |
| Nxstage Medical, INC. | $119.01 | 2021 | |
| Novo Nordisk INC | $95.62 | 2024-2025 | Rivfloza, Ozempic |
| Novartis Pharmaceuticals Corporation | $88.81 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $88.32 | 2023-2025 | Tarpeyo |
| Vifor Pharma, INC. | $81.14 | 2022-2024 | Veltassa |
| Travere Therapeutics, INC. | $79.80 | 2022-2025 | |
| Glaxosmithkline, LLC. | $58.94 | 2021-2025 | Benlysta |
| Akebia Therapeutics INC | $56.33 | 2025 | Vafseo |
| Otsuka America Pharmaceutical, INC. | $52.07 | 2024-2025 | Jynarque |
| Apellis Pharmaceuticals, INC. | $45.14 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $44.72 | 2023 | Krystexxa |
| Daiichi Sankyo INC. | $30.12 | 2024 | Injectafer |
| Alexion Pharmaceuticals, INC. | $27.08 | 2024 | Ultomiris |
| Merck Sharp & Dohme LLC | $22.63 | 2025 | Prevymis |
| Ani Pharmaceuticals, INC. | $13.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Trolinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.